董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Iain Ross | 男 | Non-Executive Chairman of the Board and Interim Principal Executive Officer | 72 | 280.95万 | 122.99 | 2025-12-18 |
| James Ede Golightly | 男 | Director | 45 | 23.66万 | 11.63 | 2025-12-18 |
| Dave Lemus | 男 | Independent Director | 63 | 13.86万 | 10.89 | 2025-12-18 |
| Rhonda L. Hellums | -- | Director,Chief Financial Officer and Principal Accounting Officer | -- | 115.09万 | 90.77 | 2025-12-18 |
| Timothy Mcinerney | -- | Director | -- | 7.75万 | 未持股 | 2025-12-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Steven Romano | 男 | Head of Research and Development | 67 | 98.19万 | 49.70 | 2025-12-18 |
| Iain Ross | 男 | Non-Executive Chairman of the Board and Interim Principal Executive Officer | 72 | 280.95万 | 122.99 | 2025-12-18 |
| Rhonda L. Hellums | -- | Director,Chief Financial Officer and Principal Accounting Officer | -- | 115.09万 | 90.77 | 2025-12-18 |
董事简历
中英对照 | 中文 | 英文- Iain Ross
-
Iain Ross在2019年12月至2020年9月担任Silence Therapeutics Plc执行主席后，自2020年9月起担任Silence Therapeutics Plc的非执行主席。他曾在2019年4月至2019年12月担任Silence Therapeutics Plc的非执行主席，并在2004年至2010年担任Silence Therapeutics Plc的主席。Ross先生在国际生命科学和技术领域拥有40多年的经验技术部门，并在包括Sandoz、Hoffman La Roche、Reed Business Publishing和Celltech Group plc在内的跨国公司中担任重要角色。他曾完成多项融资交易，并担任董事长兼首席执行官，拥有逾30年的跨境管理经验。他曾领导和参与过7次首次公开发行（ipo），并在欧洲、美国和环太平洋地区的并购交易方面有直接经验。目前，他是Redx Pharma plc（LSE）和Kazia Therapeutics Limited（ASX&NASDAQ）的非执行主席，在任命新的执行管理层之前，负责领导这两家公司的转型。此外，他还是帕拉制药有限公司（ASX）的非执行董事，并为生物技术领域的一些私营公司提供咨询。他是一位合格的特许董事，也是伦敦大学皇家霍洛威理事会的副主席。
Iain Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes multiple financing transactions having raised in excess of ￡500 million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim. - Iain Ross在2019年12月至2020年9月担任Silence Therapeutics Plc执行主席后，自2020年9月起担任Silence Therapeutics Plc的非执行主席。他曾在2019年4月至2019年12月担任Silence Therapeutics Plc的非执行主席，并在2004年至2010年担任Silence Therapeutics Plc的主席。Ross先生在国际生命科学和技术领域拥有40多年的经验技术部门，并在包括Sandoz、Hoffman La Roche、Reed Business Publishing和Celltech Group plc在内的跨国公司中担任重要角色。他曾完成多项融资交易，并担任董事长兼首席执行官，拥有逾30年的跨境管理经验。他曾领导和参与过7次首次公开发行（ipo），并在欧洲、美国和环太平洋地区的并购交易方面有直接经验。目前，他是Redx Pharma plc（LSE）和Kazia Therapeutics Limited（ASX&NASDAQ）的非执行主席，在任命新的执行管理层之前，负责领导这两家公司的转型。此外，他还是帕拉制药有限公司（ASX）的非执行董事，并为生物技术领域的一些私营公司提供咨询。他是一位合格的特许董事，也是伦敦大学皇家霍洛威理事会的副主席。
- Iain Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes multiple financing transactions having raised in excess of ￡500 million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim.
- James Ede Golightly
-
James Ede Golightly自2019年4月以来一直担任我们的董事会成员。Ede-Golightly先生目前是OxeHealth Ltd，East Balkan Properties plc和Oxford Advanced Surface Ltd.的董事长。除其他董事职务外，Ede-Golightly先生是Sarossa plc和Serendipity Capital Ltd的非执行董事，并具有作为具有国际商业利益的AIM上市公司的非执行董事的丰富经验。Ede-Golightly先生于2006年担任ORA Capital Partners的创始人，此前曾在美林投资管理公司和德国商业银行担任分析师。Ede-Golightly先生是CFA特许持有人，并拥有剑桥大学经济学硕士学位。2012年，他被英国董事学会授予年度最佳特许董事。
James Ede Golightly,previously served a member of the Board from April 2019 to June 26, 2025. He currently serves as Chairman of Oxehealth Ltd, EBP Holdings Ltd and ORA Global Ltd. Among other directorships, Mr. Ede-Golightly is also Non-Executive Director of Gulfsands Petroleum Plc and C4X Discovery Holdings Ltd. Mr. Ede-Golightly was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. Mr. Ede-Golightly is a CFA Charterholder and holds an M.A. degree in economics from Cambridge University. - James Ede Golightly自2019年4月以来一直担任我们的董事会成员。Ede-Golightly先生目前是OxeHealth Ltd，East Balkan Properties plc和Oxford Advanced Surface Ltd.的董事长。除其他董事职务外，Ede-Golightly先生是Sarossa plc和Serendipity Capital Ltd的非执行董事，并具有作为具有国际商业利益的AIM上市公司的非执行董事的丰富经验。Ede-Golightly先生于2006年担任ORA Capital Partners的创始人，此前曾在美林投资管理公司和德国商业银行担任分析师。Ede-Golightly先生是CFA特许持有人，并拥有剑桥大学经济学硕士学位。2012年，他被英国董事学会授予年度最佳特许董事。
- James Ede Golightly,previously served a member of the Board from April 2019 to June 26, 2025. He currently serves as Chairman of Oxehealth Ltd, EBP Holdings Ltd and ORA Global Ltd. Among other directorships, Mr. Ede-Golightly is also Non-Executive Director of Gulfsands Petroleum Plc and C4X Discovery Holdings Ltd. Mr. Ede-Golightly was a founder of ORA Capital Partners in 2006, having previously worked as an analyst at Merrill Lynch Investment Managers and Commerzbank. Mr. Ede-Golightly is a CFA Charterholder and holds an M.A. degree in economics from Cambridge University.
- Dave Lemus
-
Dave Lemus自2018年6月以来一直担任我们的董事会成员。Lemus先生目前是Ironshore Pharmaceuticals Inc.的首席执行官，也是索伦托医疗公司和BioHealth Innovation，Inc.的董事会成员。2016年1月至2017年5月，Lemus先生担任Medigene AG的首席运营官兼首席财务官。从2011年到2015年，他担任Sigma Tau Pharmaceuticals，Inc.的首席执行官。他曾担任MorphoSys AG的首席财务官兼执行副总裁（从1998年到2011年），在此期间他曾帮助公司在德国法兰克福证券交易所（Frankfurt Stock Exchange）上市（首次生物技术首次公开募股）。Lemus先生获得了麻省理工学院的硕士学位，并获得了马里兰大学的学士学位。Lemus先生是美国的注册会计师。
Dave Lemus has served as a member of board of directors since June 2018. Mr. Lemus is currently the Chief Executive Officer of Ironshore Pharmaceuticals Inc. and also serves on the board of directors of Sorrento Therapeutics, Inc. and Biohealth Innovation, Inc. From January 2016 to May 2017 Mr. Lemus served as Chief Operating Officer and Chief Financial Officer of Medigene AG. From 2011 to 2015 he served as Chief Executive Officer of Sigma Tau Pharmaceuticals, Inc. Mr. Lemus was Chief Financial Officer and Executive Vice President of MorphoSys AG from 1998 to 2011 during which time he helped take the company public on the Frankfurt Stock Exchange in Germany's first biotechnology initial public offering. Mr. Lemus received an M.S. from the Massachusetts Institute of Technology and received a B.S. from the University of Maryland. Mr. Lemus is a Certified Public Accountant in the United States. - Dave Lemus自2018年6月以来一直担任我们的董事会成员。Lemus先生目前是Ironshore Pharmaceuticals Inc.的首席执行官，也是索伦托医疗公司和BioHealth Innovation，Inc.的董事会成员。2016年1月至2017年5月，Lemus先生担任Medigene AG的首席运营官兼首席财务官。从2011年到2015年，他担任Sigma Tau Pharmaceuticals，Inc.的首席执行官。他曾担任MorphoSys AG的首席财务官兼执行副总裁（从1998年到2011年），在此期间他曾帮助公司在德国法兰克福证券交易所（Frankfurt Stock Exchange）上市（首次生物技术首次公开募股）。Lemus先生获得了麻省理工学院的硕士学位，并获得了马里兰大学的学士学位。Lemus先生是美国的注册会计师。
- Dave Lemus has served as a member of board of directors since June 2018. Mr. Lemus is currently the Chief Executive Officer of Ironshore Pharmaceuticals Inc. and also serves on the board of directors of Sorrento Therapeutics, Inc. and Biohealth Innovation, Inc. From January 2016 to May 2017 Mr. Lemus served as Chief Operating Officer and Chief Financial Officer of Medigene AG. From 2011 to 2015 he served as Chief Executive Officer of Sigma Tau Pharmaceuticals, Inc. Mr. Lemus was Chief Financial Officer and Executive Vice President of MorphoSys AG from 1998 to 2011 during which time he helped take the company public on the Frankfurt Stock Exchange in Germany's first biotechnology initial public offering. Mr. Lemus received an M.S. from the Massachusetts Institute of Technology and received a B.S. from the University of Maryland. Mr. Lemus is a Certified Public Accountant in the United States.
- Rhonda L. Hellums
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Timothy Mcinerney
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Steven Romano
Steven Romano，自2019年7月起担任董事会成员。Romano博士是一名获得董事会认证的精神科医生和制药高管，在广泛的治疗和疾病领域拥有25年的研发经验。Romano博士目前在万灵科PLC担任执行副总裁兼首席科学官，负责研发以及监管和医疗事务。在加入万灵科之前，Romano博士在辉瑞公司工作了16年，在那里他担任了一系列高级研发和医疗职务，责任越来越大，最近担任高级副总裁兼全球药物开发、全球创新药物业务负责人。Romano博士在密苏里大学-哥伦比亚医学院获得医学博士学位，毕业于圣路易斯华盛顿大学，获得生物学和英国文学学士学位。
Steven Romano has served as a member of board of directors since July 2019. Dr. Romano is a board-certified psychiatrist and pharmaceutical executive with 25 years of research and development experience across a wide range of therapeutic and disease areas. Dr. Romano currently serves as executive vice president and chief scientific officer at Mallinckrodt plc, where he has responsibility for research and development and regulatory and medical affairs. Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior research and development and medical roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Dr. Romano received his M.D. from the University of Missouri-Columbia School of Medicine, and graduated from Washington University in St. Louis with a bachelor's degree in biology and English literature.- Steven Romano，自2019年7月起担任董事会成员。Romano博士是一名获得董事会认证的精神科医生和制药高管，在广泛的治疗和疾病领域拥有25年的研发经验。Romano博士目前在万灵科PLC担任执行副总裁兼首席科学官，负责研发以及监管和医疗事务。在加入万灵科之前，Romano博士在辉瑞公司工作了16年，在那里他担任了一系列高级研发和医疗职务，责任越来越大，最近担任高级副总裁兼全球药物开发、全球创新药物业务负责人。Romano博士在密苏里大学-哥伦比亚医学院获得医学博士学位，毕业于圣路易斯华盛顿大学，获得生物学和英国文学学士学位。
- Steven Romano has served as a member of board of directors since July 2019. Dr. Romano is a board-certified psychiatrist and pharmaceutical executive with 25 years of research and development experience across a wide range of therapeutic and disease areas. Dr. Romano currently serves as executive vice president and chief scientific officer at Mallinckrodt plc, where he has responsibility for research and development and regulatory and medical affairs. Prior to joining Mallinckrodt, Dr. Romano spent 16 years at Pfizer, Inc. where he held a series of senior research and development and medical roles of increasing responsibility, culminating in his most recent position as SVP, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Dr. Romano received his M.D. from the University of Missouri-Columbia School of Medicine, and graduated from Washington University in St. Louis with a bachelor's degree in biology and English literature.
- Iain Ross
Iain Ross在2019年12月至2020年9月担任Silence Therapeutics Plc执行主席后，自2020年9月起担任Silence Therapeutics Plc的非执行主席。他曾在2019年4月至2019年12月担任Silence Therapeutics Plc的非执行主席，并在2004年至2010年担任Silence Therapeutics Plc的主席。Ross先生在国际生命科学和技术领域拥有40多年的经验技术部门，并在包括Sandoz、Hoffman La Roche、Reed Business Publishing和Celltech Group plc在内的跨国公司中担任重要角色。他曾完成多项融资交易，并担任董事长兼首席执行官，拥有逾30年的跨境管理经验。他曾领导和参与过7次首次公开发行（ipo），并在欧洲、美国和环太平洋地区的并购交易方面有直接经验。目前，他是Redx Pharma plc（LSE）和Kazia Therapeutics Limited（ASX&NASDAQ）的非执行主席，在任命新的执行管理层之前，负责领导这两家公司的转型。此外，他还是帕拉制药有限公司（ASX）的非执行董事，并为生物技术领域的一些私营公司提供咨询。他是一位合格的特许董事，也是伦敦大学皇家霍洛威理事会的副主席。
Iain Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes multiple financing transactions having raised in excess of ￡500 million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim.- Iain Ross在2019年12月至2020年9月担任Silence Therapeutics Plc执行主席后，自2020年9月起担任Silence Therapeutics Plc的非执行主席。他曾在2019年4月至2019年12月担任Silence Therapeutics Plc的非执行主席，并在2004年至2010年担任Silence Therapeutics Plc的主席。Ross先生在国际生命科学和技术领域拥有40多年的经验技术部门，并在包括Sandoz、Hoffman La Roche、Reed Business Publishing和Celltech Group plc在内的跨国公司中担任重要角色。他曾完成多项融资交易，并担任董事长兼首席执行官，拥有逾30年的跨境管理经验。他曾领导和参与过7次首次公开发行（ipo），并在欧洲、美国和环太平洋地区的并购交易方面有直接经验。目前，他是Redx Pharma plc（LSE）和Kazia Therapeutics Limited（ASX&NASDAQ）的非执行主席，在任命新的执行管理层之前，负责领导这两家公司的转型。此外，他还是帕拉制药有限公司（ASX）的非执行董事，并为生物技术领域的一些私营公司提供咨询。他是一位合格的特许董事，也是伦敦大学皇家霍洛威理事会的副主席。
- Iain Ross, based in the UK, is an experienced Director and has served on a number of Australian company boards. He is Chairman of Silence Therapeutics plc (LSE & NASDAQ:SLN), ReNeuron Group plc (LSE:RENE) and BiVitctriX Therapeutics plc (LSE:BVX) as well as unlisted Biomer Technology Limited. In his career he has held senior positions in Sandoz AG, Fisons Plc, Hoffmann-La Roche AG and Celltech Group Plc and also undertaken a number of start-ups and turnarounds on behalf of banks and private equity groups. His track record includes multiple financing transactions having raised in excess of ￡500 million, both publicly and privately, as well as extensive experience of divestments and strategic restructurings and has over 25 years in cross-border management as a Chairman and CEO. He has led and participated in 8 Initial Public Offerings,(5 LSE, 1 ASX, 2 NASDAQ) and has direct experience of mergers and acquisitions transactions in Europe, USA and the Pacific Rim.
- Rhonda L. Hellums
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介